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Abstract 
Background: Non-tuberculous mycobacteria (NTM) are increasingly reported worldwide associated with human dis-
ease. Defining the significance of NTM in settings with endemic tuberculosis (TB) requires the discrimination of NTM 
from TB in suspect patients. Correct and timely identification of NTM will impact both therapy and epidemiology of TB 
and TB-like diseases. The present study aimed at determining the frequency and diversity of NTM among TB suspects 
in northeastern Tanzania.
Methods: A cross-sectional study was conducted between November 2012 through January 2013. Seven hundred 
and forty-four sputum samples were collected from 372 TB suspects. Detection was done by using phenotypic, Geno-
Type® Mycobacterium CM/AS kits, 16S rRNA and hsp65 gene sequencing for identification of isolates not identified by 
Hain kits. Binary regression model was used to analyse the predictors of NTM detection.
Results: The prevalence of NTM was 9.7 % of the mycobacterial isolates. Out of 36 patients with confirmed NTM 
infection, 12 were HIV infected with HIV being a significant predictor of NTM detection (P < 0.001). Co-infection with 
Mycobacterium tuberculosis (M. tb) was found in five patients. Twenty-eight NTM isolates were identified using Geno-
Type® Mycobacterium CM/AS and eight isolates could not be identified. Identified species included M. gordonae and 
M. interjectum 6 (16.7 %), M. intracelullare 4 (11.1 %), M. avium spp. and M. fortuitum 2 (5.5 %), M. kansasii, M. lentiflavum, 
M. simiae, M. celatum, M. marinum 1 (2.8 %) each. Of isolates not identified to subspecies level, we identified M. kuma-
motonense (2), M. intracellulare/kansasii, M. intermedium/triplex, M. acapulcensis/flavescens, M. stomatepiae, M. colombi-
ense and M. terrae complex (1) each using 16S rRNA sequencing. Additionally, hsp65 gene sequencing identified M. 
kumamotonense, M. scrofulaceum/M. avium, M. avium, M. flavescens/novocastrense, M. kumamotonense/hiberniae, M. 
lentiflavum, M. colombiense/M. avium and M. kumamotonense/terrae/hiberniae (1) each. Results of the 16S rRNA and 
hsp65 gene sequencing were concordant in three and discordant in five isolates not identified by GenoType® Myco-
bacterium CM/AS.
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Background
Over the past decades, the prevalence of pulmonary 
nontuberculous mycobacteria (NTM) is increasingly 
reported worldwide. However, epidemiological and sur-
veillance data of NTM infections are still limited [1]. 
Defining the epidemiology of NTM diseases in most 
resource poor settings like Tanzania is more challenging 
than its well documented relative Mycobacterium tuber-
culosis complex (MTC) [2].
Due to their ubiquitous presence in the environment, 
exposure to NTM is likely common, as they can colonize 
the respiratory tract without causing disease such that 
finding NTM in respiratory secretions does not neces-
sarily have clinical implications in all patients [3–5]. 
Differentiating true NTM lung infection from contami-
nation and/or colonization is difficult; hence, the pres-
ence of acid-fast bacilli (AFB) positive by microscopy of 
a respiratory sample or culture poses major diagnostic 
challenge. Increasingly, NTM are becoming recognized 
as true pathogens and important causes of human infec-
tions [6, 7].
Information on the role, contribution and burden of 
NTM in aetiology of TB–like syndromes is limited in 
many sub-Saharan African countries endemic to TB and 
HIV [8–10]. Lack of rapid and accurate methods to diag-
nose AFB positive pulmonary infections due to NTM 
results in misdiagnosis and mismanagement of pulmo-
nary TB in such settings. Correct and timely identifica-
tion of NTM is particularly urgent for both therapy and 
epidemiology, since infections with different mycobacte-
rial species demand different management approaches 
[11, 12].
Tanzania is among the 22 high burden countries 
(HBCs) in the world with high prevalence of TB. On 
average, 61,500 new TB patients are notified annually 
[13]. Patients with AFB positive sputum or with chest 
radiographic findings presumptive of active TB, who 
do not respond to general antimicrobials, are generally 
assumed positive for TB. As a general guideline, patients 
are empirically treated with first line anti-TB drugs for 
6 months.
Since several TB-like syndromes could also be due to 
NTM, inconclusive diagnosis of pulmonary TB would 
result in over-diagnosis of TB and hence miss–manage-
ment of both TB and NTM infections.
Invention of DNA strip technology (line probe assays) 
based on reverse hybridization of PCR products to their 
complementary oligonucleotide probes has revolution-
ized the diagnosis of NTM. Commercial DNA strip assay 
kits GenoType® Mycobacterium CM/AS (Hain Life sci-
ence GmbH, Nehren, Germany); GenoType® CM/AS for 
detection of common and additional NTM species have 
been widely and successfully used as rapid molecular 
tools in the diagnosis of NTM both in resource poor and 
developed countries. However, cross–reactivity of DNA 
probes between mycobacterial species has been reported, 
leading to incorrect diagnosis and treatment of patients 
[14, 15]. Use of molecular techniques targeting the 16S 
rRNA and hsp65 genes have been useful in diagnosis and 
speciation of NTM, including those which are dead or 
uncultivable [16].
The objective of the present study was therefore to 
determine the frequency and diversity of NTM among 
TB suspects in Northeastern Tanzania using conven-
tional phenotypic methods, GenoType® Mycobacte-
rium CM/AS kits and 16S rRNA as well as hsp65 gene 
sequencing.
Our findings suggest that NTM infections may play a 
vital role in causing lung disease and hence impacting 
management of TB in endemic settings like Tanzania. 
Therefore, the need to consider NTM in TB control pro-
grammes in such settings is urgent.
Methods
Study settings
The study was conducted in two peripheral diagnostic 
centres (PDCs) of Ngamiani and Makorora. The centres 
serve as primary catchment for TB diagnosis in Tanga 
municipal and two hospitals of Muheza Designated Dis-
trict Hospital (MDDH) and Bombo referral hospital. 
Tanga is among the top 10 regions with high TB notifica-
tion in Tanzania with annual TB notification cases for the 
entire region being about 3852 cases, and the TB preva-
lence of 217/100,000 and 244/100,000 in urban and rural 
settings respectively as per national prevalence survey, 
2012 [17].
Conclusion: NTM infections may play a vital role in causing lung disease and impact management of TB in endemic 
settings. GenoType® Mycobacterium CM/AS represents a useful tool to identify clinical NTM infections. However, 16S 
rRNA gene sequencing should be thought for confirmatory diagnosis of the clinical isolates. Due to the complexity 
and inconsistence of NTM identification, we recommend diagnosis of NTM infections be centralized by strengthening 
and setting up quality national and regional infrastructure.
Keywords: Nontuberculous mycobacteria, Peripheral diagnostic centres, Human immunodeficiency virus (HIV), 
Tanzania
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Study design
A cross-sectional study was carried out between Novem-
ber 2012 through January 2013. A total of 744 spot and 
morning sputum samples were collected from 372  TB 
suspected patients self–presenting at the PDCs and 
hospitals. All patients presenting to the diagnostic cen-
tre with any of the following symptoms were included: 
presences of symptoms suggestive of TB for a period 
of ≥2  weeks, night sweats, fatigue, unexpected loss of 
weight, and fever. Three sputum samples were collected 
from patients (one on the spot during the first visit, one 
early morning and another spot the following morning). 
Early morning sputa were stored at −20  °C and later 
transported to the Mycobacteriology laboratory at the 
University hospital Leipzig, Germany for culture and 
molecular identification.
Smear microscopy and culture isolation
Direct smear microscopy using Ziehl Neelsen (ZN) 
or fluorescent stains were performed at the respective 
study sites by experienced laboratory technicians and the 
results recorded in accordance to the WHO/IUTLD and 
National Tuberculosis and Leprosy Programme (NTLP) 
guidelines [18, 19].
In Leipzig, all the sputum specimens were processed 
by the standard N-acetyl-L-cysteine (NALC)-NaOH 
method [20]. Briefly, 10  ml of 0.5  % N-acetyl-cysteine 
(NALC) solution was added to each sample, specimens 
were then incubated at room temperature on a shaker 
for 20  min, followed by addition of 30  ml of phosphate 
buffered saline (PBS) pH 6.8 for neutralization and subse-
quently centrifuged at 3000×g for 20 min. The sediments 
were resuspended in 1 ml PBS after discarding the super-
natant. All the decontamination procedure followed the 
Deutsches Institut für Normung (DIN) recommenda-
tions for the detection of mycobacteria [21].
About 2–3 drops of resuspended specimens were 
inoculated on Lowenstein-Jensen (LJ), Gottsacker, and 
Coletsos slants (Artelt-ENCLIT GmbH, Germany) sup-
plemented with antibiotics (Polymyxin B (200,000  IU/
liter), Amphotericin B (10  mg/liter), Carbenicillin 
(50  mg/liter), and Trimethoprim (10  mg/liter) (PACT). 
Cultures were incubated for 8  weeks at 37  °C and read 
weekly.
Examination and reporting of smear microscopy was 
performed by fluorescent microscopy. Subsequently, 
0.5 ml of each specimen was inoculated into BacT/Alert 
bottles supplemented with antibiotics PACT and incu-
bated in an automated BacT/Alert 3D System (Biomé-
rieux, Marcy l’Etoile, France) liquid culture system for 
8 weeks. Culture not showing any growth after 8 weeks of 
incubation was considered negative. Positive BacT/Alert 
bottles were checked for purity by plating a drop from 
each positive bottle onto blood agar (BA) plate to rule out 
false positive results due to bacterial contamination and 
simultaneously ZN stain was performed to confirm pres-
ence of AFB positive results.
Phenotypic identification
Slants containing pure cultures of AFB were assessed for 
growth rate and pigment accumulation on LJ, Gottsacker 
or Coletsos slants (at 30 °C, 37 °C and 45 °C). NTM iso-
lates were grouped based on Runyon classification and 
results compared with those of molecular methods.
DNA extraction
Mycobacterial DNA was extracted from heat–inactivated 
AFB isolates. Briefly, bacteria suspended in 500 µl sterile 
water or 1  ml directly from positive BacT/Alert bottles 
were inactivated at 80 °C for 20 min, then ultra-sonicated 
at 35  kHz and heated at 100  °C for 10  min each treat-
ment and centrifuged at 16,100×g two times for 5  min. 
The supernatant was taken as template DNA. Genomic 
DNA of the H37Rv strain and sterile distilled water were 
used as positive and negative controls respectively for all 
molecular procedures.
Identification of NTM by GenoType® Mycobacterium  
CM/AS assay
All isolates identified as NTM based on their cultural 
characteristics and confirmed by ZN staining were sub-
jected to further definitive identification using two com-
mercial kits, the GenoType® Mycobacterium CM for 
detection of common NTM. Isolates not identified by 
GenoType® CM assay were further tested with the Geno-
Type® AS assay for additional NTM. All the procedures 
followed manufacturer’s instructions.
DNA sequence analysis
All isolates not identified to the species level by the CM/
AS assay were analyzed by 16S rRNA and hsp65 gene 
sequencing. For sequence analysis of the 16S rRNA gene 
was done according to [22] using the primers 285 and 
264 for generating the PCR product (1037 bp) and primer 
271 for sequencing. For hsp65 gene sequencing, PCR was 
done according to [23] using the primers 21M13TB11/
M13TB12 generating a 441  bp fragment. For sequenc-
ing, the primer M13/pUC forward was used. The prim-
ers were purchased from Jena Bioscience, Jena, Germany. 
The PCR products were purified for sequencing using 
QIAquick PCR Purification Kit or alternatively QIAquick 
Gel Extraction Kit according to the manufacturer’s 
instructions. Sequencing was done by GATC Company 
(Konstanz, Germany). The raw data were analyzed at the 
FLI using the National Centre for Biotechnology Infor-
mation (NCBI) BLAST software optimized for highly 
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similar sequences (http://blast.ncbi.nlm.nih.gov). Strain 
identification was based on the BLAST hit with the high-
est scores combined with greatest sequence coverage 
and identity. Reference strains with the highest similarity 
score as present in the NCBI database were used as refer-
ences for the similarity assessment.
Data analysis
Demographic and clinical data were cleared and analysed 
by SPSS version 11.5 for Windows (SPSS Inc., Chicago, 
IL) software package. Binary regression model was used 
to analyse the predictors of NTM isolation. One-way 
analysis of variance (ANOVA) was used to determine 
trend analysis across ordered groups. P value <0.05 was 
considered statistically significant. GenoType® Mycobac-
terium CM/AS assay results were interpreted based on 
manufacturers instruction.
Ethical clearance
The protocol for this study was reviewed and approved by 
the Ethical Committee of the National Institute for Medi-
cal Research (NIMR), Dar es Salaam, Tanzania. Written 
informed consent was obtained from the patients or rela-
tives of the patients, where the patients could not read 
and write.
Results
A total of 744 sputum samples were collected from 372 
TB suspects who self–presented at two PDCs and two 
hospitals in Tanga, northeastern, Tanzania. The propor-
tion of males 196 (52.7 %) was higher than that of female 
176 (47.3 %). The median age of the patients was 40 years 
(range 7–88 years).
Demographic characteristics of patients and risk factors 
associated with NTM
Demographic data and risk factors associated with NTM 
infections are shown in (Tables  1, 2). The overall fre-
quency of the patients with NTM in the study was 9.7 %; 
HIV positivity was found to be associated with NTM 
infection among the factors analysed, with a statistical 
significance of (OR 3.86, 95 % CI [1.79–8.3], P < 0.001). 
There was no association between NTM and other fac-
tors analysed.
Culture Results
Of the 372 patients, positive mycobacterial cultures were 
obtained in 121 (32.5  %) patients and among these 36 
(9.7  %) patients harboured NTM, which are subject of 
this paper. From each patient three sputum samples were 
analysed for NTM growth. In total, 101 sputum sam-
ples were positive for NTM by culture. In this regard, 
29 patients (80.6  %) were positive for NTM growth 
in all three samples and seven patients (19.4  %) were 
positive for NTM only in two out of the three samples. 
NTM without any other coinfections were detected in 
21 (58.3  %) patients. NTM coinfection with HIV was 
found in 11 (30.6 %) patients, with MTBC in three (8.3 %) 
patients and NTM with both HIV and MTBC coinfec-
tions in one (2.8  %) patient. One patient was simulta-
neously positive for NTM plus Nocardia spp. (data not 
shown) (Table 3). None of the patients had mixed NTM 
infections.
Of the 121 patients, 81 (66.9  %) patients had positive 
smear microscopy for AFB and 40 (33.1 %) patients were 
smear negative at the laboratory in Leipzig. On the other 
hand, of those 121 patients with positive culture results, 
64 (52.9  %) patients had positive smear microscopy for 
AFB and 56 (46.3 %) patients had negative smear micros-
copy for AFB at local PDCs/hospitals, whereas only one 
(0.8  %) patient had smear positive AFB at local PDCs/
hospitals but negative smear microscopy and culture in 
Leipzig.
Phenotypic identification of the NTM
Based on their growth characteristics and pigment pro-
duction, the isolates were grouped into different Runyon 
groups [24]. Eighteen isolates were classified as sco-
tochromogenic (Runyon II), 13 as nonphotochromo-
genic (III), 4 as photochromogenic (Runyon I) and 1 as 
rapid growing mycobacteria (Runyon IV). The results 
were comparable to the molecular detection by Hain kit 
results (Table 4).
Distribution of mycobacterial isolates by site
Results of genotyping using GenoType® MTBC for the 
MTC and GenoType® Mycobacterium CM/AS for NTM 
isolates at each site showed that the prevalence of M. 
tuberculosis alone were 10.4, 22.7, 24.2 and 26.9  % at 
Makorora HC, Ngamiani HC, Bombo RH and MDDH 
respectively. The prevalence of NTM alone were 10.4, 
11.0, 1.6 and 8.2  % at Makorora HC, Ngamiani HC, 
Bombo RH and MDDH respectively (Table 1).
Identification of NTM isolates GenoType® Mycobacterium 
CM/AS
Identification of NTM isolates to species level by Geno-
Type® Mycobacterium CM/AS kits was achieved in 28 
(77.8  %) isolates with GenoType® Mycobacterium CM 
identifying 23 (63.9  %) of the isolates and GenoType® 
Mycobacterium AS identifying 5 (13.9  %) isolates. On 
the other hand, eight (22.2 %) out of 36 isolates could not 
be identified by either kit. M. gordonae and M. interjec-
tum were the most frequently identified with 6 (16.7 %) 
isolates each, followed by M. intracellulare 4 (11.1  %), 
M. scrofulaceum 3 (8.3  %), M. avium spp. 2 (5.5  %), M. 
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fortuitum 2 (5.5 %), M. kansasii 1 (2.8 %), M. lentiflavum 
1 (2.8 %), M. simiae 1 (2.8 %), M. celatum 1 (2.8 %) and 
M. marinum 1 (2.8 %) (Table 4).
Table 1 Demographic characteristics and laboratory findings of the patients with NTM infections stratified by site
HC health Centre, MDDH Muheza Designated District Hospital, MTBC M. tuberculosis complex, NTM nontuberculous mycobacterium
Demographic and risk 
factors
Makorora HC  
n = 48 (%)
Ngamian HC  
n = 128 (%)
Bombo RH  
n = 62 (%)





 Female 20 (41.7) 56 (43.7) 40 (64.5) 60 (44.8) 176
 Male 28 (58.3) 72 (56.3) 22 (35.5) 74 (55.2) 196
 Age: Mean (SD) 45.1 (18.9) 39.4 (17.6) 38.3 (15.6) 42.9 (16.9)
Age groups (years)
 <20 1 (2.1) 8 (6.3) 6 (9.7) 6 (4.5) 21
 20–40 13 (27.1) 69 (53.9) 23 (37.1) 51 (38.1) 156
 40–60 22 (45.8) 29 (22.6) 27 (43.5) 57 (42.5) 135
 >60 12 (25.0) 22 (17.2) 6 (9.7) 20 (14.9) 60
Residence
 Urban 39 (81.3) 97 (75.8) 43 (69.4) 28 (20.9) 207
 Rural 9 (18.7) 31 (24.2) 19 (30.6) 106 (79.1) 165
Occupation
 Peasants 24 (50.0) 33 (25.8) 31(50.0) 68 (50.8) 156
 Housewife 11 (22.9) 16 (12.5) 18 (29.0) 24 (17.9) 69
 Business 5 (10.4) 24 (18.8) 5 (8.1) 11 (8.2) 45
 Others 8 (16.7) 55 (42.9) 8 (12.9) 31 (23.1) 102
 Prevalence of MTBC 
alone
5 (10.4) 29 (22.7) 15 (24.2) 36 (26.9) 85
 Prevalence of NTM 
alone
5 (10.4) 14 (11.0) 1 (1.6) 11 (8.2) 31
 Prevalence of MTB 
+NTM
0 3 (3.2) 1 (1.6) 1 (0.7) 5
Concurrent conditions
 HIV + ve 12 (25.0) 14 (10.9) 13 (30.0) 14 (10.4) 53
 HIV − ve 7 (14.6) 87 (68.0) 1 (1.6) 19 (14.2) 114
 Unknown 29 (60.4) 27 (21.1) 48 (77.4) 101 (75.4) 205
Previous TB
 Yes 9 (18.7) 33 (25.8) 1 (1.6) 16 (11.9) 59
 No 39 (81.3) 95 (74.2) 61 (98.4) 118 (88.1) 313
Table 2 Risk factors associated with  NTM infection 
among  suspected TB patients attending PDCs/hospitals 
in  north-eastern, Tanzania from  November 2012 to  Janu-
ary 2013
OR odd ratio, CI confidence interval
* P value is statistically significant at P < 0.05
OR 95 % CI P value
Gender 0.83 0.42–1.66 0.6
Age 1.02 0.52–2.04 0.95
Location 0.96 0.48–1.9 0.9
Occupation 0.95 0.43–2.1 0.8
HIV positive 3.86 1.79–8.3 0.001*
Previous TB 0.84 0.31–2.26 0.7
Table 3 Comorbidity of  NTM with  either M.tb and  or HIV 
among individuals with NTMs
Type of infection No. of individuals (%)
NTM alone 21 (58.3 %)
HIV + NTM 11 (30.6 %)
NTM + M.tb 3 (8.3 %)
HIV + NTM + M.tb 1 (2.8 %)
Total 36
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16S rRNA gene and hsp65 gene sequencing
Eight isolates not previously identified by the GenoType® 
Mycobacterium CM/AS kits were analysed by 16S rRNA 
gene sequencing and additionally by hsp65 gene sequenc-
ing. Three of eight species yielded comparable results 
with both genes while five hsp65 analyses gave results dif-
ferent from 16S rRNA gene sequencing.
16S rRNA gene sequencing for the eight isolates 
yielded M. kumamotonense (n  =  2), M. intracelullare/
kansasii, M. intermedium/triplex, M. acapulcensis/faven-
scens, M. stomatepiae, M. colombiense and M. terrae 
complex (n = 1). The results with the respective lengths 
of the sequenced DNA stretches are shown in (Table 5).
Discussion
While the epidemiology of TB is well documented, the 
prevalence and epidemiology of NTM in Tanzania is 
largely unravelled [25]. NTM pulmonary infections are 
increasingly reported because of increased populations 
at-risk due to HIV infection, old age, other immunosup-
pressive conditions, increased awareness and improved 
diagnostic facilities especially in developed countries [26, 
27].
In Tanzania, the existing supposition is that most indi-
viduals presenting with pulmonary symptoms reflecting 
mycobacterial diseases are infected with MTC. Chances 
that NTM are missed during diagnosis is to a great extent 
attributed to poor diagnostic capabilities for culture and 
identification of NTM, endemic nature of MTC, overbur-
den by diseases like malaria and HIV. Furthermore, lack 
of awareness among public health personnel and lack of 
standardized or accepted criteria to properly define and 
report NTM have all resulted to less attention on the 
NTM infections.
In this study, the overall frequency of patients with 
NTM detected by Hain kits among pulmonary TB sus-
pects population was 9.7  %. We identified M. gordonae 
and M. interjectum with 6 (16.7 %) isolates each account-
ing for about one-third of all NTM isolates, M. intracelull-
are 4 (11.1 %), M. avium spp. and M. fortuitum 2 (5.5 %), 
M. kansasii, M. lentiflavum, M. simiae, M. celatum, M. 
marinum 1 (2.8  %) isolate each. Additionally, eight iso-
lates, which gave no signal with GenoType® Mycobac-
terium CM/AS kits were identified by 16S rRNA gene 
sequencing. These isolates were assigned to the species 
M. kumamotonense (2), M. intracellulare/kansaii (1), M. 
intermedium/M. triplex (1), M. acapulcensis/M. flavescens 
Table 4 Species distribution of  the NTM isolated 
from  PDCs/hospitals in  northeastern Tanzania based 
on Runyon grouping and GenoType® Mycobacterium CM/
AS
Prevalence of NTM  
infection
Runyon group n = 36 (%) Assay
M. gordonae II 6 (16.7) GenoType CM
M. interjectum II 6 (16.7) GenoType CM
M. intracellulare III 4 (11.1) GenoType CM
M. scrofulaceum II 3 (8.3) GenoType CM
M. avium spp. III 2 (5.5) GenoType CM
M. fortuitum III 2 (5.5) GenoType CM
M. kansasii I 1 (2.8) GenoType AS
M. lentiflavum II 1 (2.8) GenoType AS
M. simiae I 1 (2.8) GenoType AS
M. celatum III 1 (2.8) GenoType AS
M. marinum I 1 (2.8) GenoType AS
NTM not identified 8 (22.2)
Table 5 NTM species identified based on 16S rRNA gene and hsp65 gene sequencing
Strain ID 16S rRNA gene sequencing Identity/sequence length (bp) hsp65 gene sequencing Identity/sequence length (bp)
TZ095 M. kumamotonense 558/559 M. kumamononense 357/357
TZ141 M. intracellulare 922/928 M. scrofulaceum 343/359
M. kansasii 924/928 M. avium complex 343/360
TZ145 M. intermedium 902/916 M. avium complex 300/315
M. triplex 896/916
TZ147 M. acapulcensis 918/918 M. flavescens 369/372
M. flavescens 912/919 M. novocastrense 368/372
TZ149 M. kumamotonense 928/928 M. kumamotonense 356/357
M. hiberniae 382/384
TZ217 M. stomatepiae 570/570 M. lentiflavum 362/372
TZ224 M. colombiense 928/928 M. colombiense 378/385
M. avium complex 376/385
TZ294 M. terrae complex 923/931 M. kumamotonense 368/384
M. terrae 364/384
M. hiberniae 363/384
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(1), M. stomatepiae (1), M. colombiense (1) and M. terrae 
(1). Additionally, hsp65 gene sequencing was conducted if 
the 16S rRNA sequences were not discriminatory in order 
to confirm especially the ambiguous species assignments. 
However, only three of eight isolates both genes indicated 
the same species, for five isolates discordant results were 
achieved by sequencing both genes (Table 5). Sequencing 
of different genes used for bacterial species identification 
may yield inconsistent results. The problem is even more 
complicated with mycobacteria which are characterized 
by interspecies similarity clearly higher than in other bac-
teria [28, 29]. These results emphasise the difficulties of 
species identification for NTM. Therefore, it is of great 
importance to standardize the methods in order to gen-
erate comparable results between different laboratories, 
countries and continents.
M. kumamotonense, M. acapulcensis M. novocastrense, 
M. stomatepiae, and M. hiberniae determined by either 
16S rRNA or hsp65 in this study (Table  5) have been 
reported elsewhere in the world. Some of which have 
been associated with human diseases and others isolated 
from the environment [30–33]. To the best of our under-
standing, these species have not previously reported in 
Tanzania.
Our findings are in agreement with findings from other 
studies in Tanzania and Africa which indicated increas-
ing prevalence of NTM [9, 34, 35]. Whether there exist 
geographic variations in the diversity of NTM in Tanza-
nia is not clear since this study focused only on patients 
residing in a more or less similar geographic location 
along the northeastern coast of Tanzania.
Understanding the distribution and clinical impact 
of NTM is of public health significance, as it addresses 
concerns of over diagnosis of tuberculosis and potential 
under treatment of NTM infections. As reported pre-
viously [35], there exist quite diverse species of NTM 
among humans, livestock and wildlife [36]; this therefore 
stresses need to investigate the distribution and clinical 
impact of different NTM species in Tanzania.
Analysis of the predictors of NTM infection in this 
study shows lack of association among gender, age, area 
of residence and occupation in patients diagnosed with 
NTM. However, need to study NTM infections in TB 
endemic settings like Tanzania through a larger cohort 
and evaluation of their impact on TB disease is particu-
larly urgent. Though in the present study we did not per-
form drug susceptibility testing for the isolated NTM, 
such patients may erroneously regarded as having MDR 
isolates.
Immunocompromised individuals due to HIV/AIDS 
are at a high risk of NTM infections, with M. intracel-
lulare, and M. avium complex (MAC) being frequently 
reported [37–39].
Findings from this study show that individuals with 
HIV positive status had a varying range of NTM infec-
tions and HIV was an important predictor of NTM 
detection (OR 3.86, 95  % CI [1.79–8.3], p  <  0.001). The 
identified NTM included M. scrofulaceum (2), M. avium 
spp. (2), M. gordonae (2), M. intracelullare (1), M. lenti-
flavum (1), M. celatum (1) and M. interjectum (1). Two of 
the isolates from HIV positive cases, not identified by the 
Hain kits, were found to belong to M. kumamotonense 
and M. intracellulare by 16S rRNA sequencing.
MAC and rarely identified species of M. lentiflavum 
and M. sherrisii were reported among HIV positive 
patients with pulmonary disease in Zambia and Tanzania 
[9, 34, 40]. M. sherrisii which was found to be commonly 
associated with HIV individuals in northern Tanza-
nia [34], was not detected in this patient population. M. 
celatum commonly isolated from human respiratory 
tract specimens is also known to be pathogenic to HIV 
patients and sometimes non–immunocompromised 
patients [41], whereas, M. gordonae a common contami-
nant of water supply, soil, casual resident in human spu-
tum and gastric lavage specimens is rarely (e.g. AIDS) if 
ever implicated in disease processes [41].
NTM co-infections with M. tuberculosis disease are 
rarely diagnosed owing to overlapping clinical manifesta-
tions [10]. Our results show that five (1.3 %) individuals 
had both M. tuberculosis and NTM which included M. 
scrofulaceum (2), M. interjectum (1), M. gordonae (1) and 
one isolate not identified by Hain kits was identified as M. 
kumamotonense by 16S rRNA sequencing. Although it 
may be assumed that patients with such co-infections in 
many cases manifest symptoms mainly due to M. tuber-
culosis, the role of such co–infections underscore the 
need for further research to determine their contribution 
in the disease pathogenesis, severity and progression.
NTMs pose a major challenge for TB treatment pro-
grammes since such patients are managed mainly on 
the basis of smear microscopy which is not suitable to 
differentiate between MTC and NTM, but also major 
drawbacks lie on limited sensitivity and specificity of 
symptoms and radiology [8]. Culture on the other hand, 
is the gold standard but is time consuming, demands use 
of different types of media and longer incubation for opti-
mization of growth. Since such elaborate culture algo-
rithms are scarce outside the reference centres, NTMs 
warrant a special emphasis as possible cause of disease.
Although we cannot certainly conclude whether the 
isolated NTM merit to be classified as cause of infection/
disease in each particular case, a mere presence of NTM 
in a particular case could make the decision on the diag-
nosis more complex. Need for public hygiene education 
is particularly high, since NTM are mostly found in the 
environment (water, soil). If people exert better hygiene 
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management in their homes and food preparation, ani-
mal keeping, water boiling before drinking and so on, the 
risk of being infected would decrease, especially for per-
sons at risk such as children, elderly, and immunocom-
promised individuals.
Limitations
A number of factors could have limited our findings. 
Firstly, lack of preliminary laboratory data on the chronic 
patients presented limited us from determining whether 
they had been infected only by an NTM or they primar-
ily had coinfection with M. tuberculosis. Secondly, lack 
of follow up limits the capacity to establish patients’ out-
comes especially with NTM disease in many resource 
poor settings. Moreover, the true prevalence of NTM 
can only be assessed through a wider epidemiological 
study. These findings were communicated to the Medi-
cal Research Coordinating Committee where National 
Tuberculosis Control Program is represented. However, 
we are not sure if NTLP guided starting of appropri-
ate treatment for NTM since there are no clear national 
guidelines for management of NTMs. This makes these 
findings very important as they may serve as baseline 
data for the NTLP to develop guidelines for management 
of NTMs.
In conclusion, our findings suggest that there is a 
diverse range of NTM infections, which may play a vital 
role in causing lung disease and impact the management 
of TB in TB-endemic settings leading to misdiagnosis 
and inappropriate treatment of MDR cases particularly 
the clinically ‘‘chronic cases’’. This highlights the need to 
consider NTM when treating patients with putative TB 
treatment failures. Moreover, fundamental information 
that meets ATS/IDSA diagnostic criteria for diagnosis of 
pulmonary NTM is needed to improve the understand-
ing of NTM disease. There is an urgent need of formu-
lating standardized criteria for defining and reporting 
NTM infections. We recommend that laboratory diag-
nosis of NTM infections be centralized by strength-
ening and setting up quality national and regional 
infrastructure.
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